Johnson & Johnson (FRA:JNJ)
Germany
· Delayed Price · Currency is EUR 136.36
+0.20 (0.15%)
Last updated: Jun 10, 2025
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B USD in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
3.97
Revenue / Employee
$646.86K
Employees
138,100
Market Cap
327.11B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 109.03B |
| Rheinmetall AG | 10.48B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Energy AG | 37.44B |
| Siemens Healthineers AG | 23.14B |
Johnson & Johnson News
- 1 day ago - Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know - Benzinga
- 1 day ago - Johnson & Johnson denies engaging in illegal DEI practices after group makes civil rights complaint - Fox News
- 2 days ago - Les Squires obituary - The Guardian
- 4 days ago - Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? - Market Watch
- 7 days ago - Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation - Benzinga
- 7 days ago - Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma - Benzinga
- 7 days ago - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity - PRNewsWire
- 7 days ago - Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients - PRNewsWire